User:Mr. Ibrahem/Erlotinib

Mr. Ibrahem/Erlotinib
Clinical data
Trade names	Tarceva
Other names	Erlotinib hydrochloride
AHFS/Drugs.com	Monograph
MedlinePlus	a605008
License data	EU EMA: by INN; US DailyMed: Erlotinib; US FDA: Erlotinib;
Pregnancy; category	AU: C; ;
Routes of; administration	By mouth tablets
Legal status
Legal status	UK: POM (Prescription only); US: ℞-only;
Pharmacokinetic data
Bioavailability	59%
Protein binding	95%
Metabolism	Liver (mainly CYP3A4, less CYP1A2)
Elimination half-life	36.2 hrs (median)
Excretion	>98% as metabolites, of which >90% via feces, 9% via urine
Identifiers
	IUPAC name N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy); quinazolin-4-amine;
Chemical and physical data
Formula	C22H23N3O4
Molar mass	393.443 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COCCOc1cc2c(cc1OCCOC)ncnc2Nc3cccc(c3)C#C;
	InChI InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25) ; Key:AAKJLRGGTJKAMG-UHFFFAOYSA-N ;
	(verify)

Erlotinib, sold under the brand name Tarceva among others, is a medication used to treat non-small cell lung cancer (NSCLC) and pancreatic cancer.^[3] Specifically it is used for NSCLC with mutations in the epidermal growth factor receptor (EGFR) — either an exon 19 deletion (del19) or exon 21 (L858R) substitution mutation — which has spread to other parts of the body.^[3] It is taken by mouth.^[3]

Common side effects include rash, diarrhea, muscle pain, joint pain, and cough.^[3]^[4] Serious side effects may include lung problems, kidney problems, liver failure, gastrointestinal perforation, stroke, and corneal ulceration.^[3] Use in pregnancy may harm the baby.^[3] It is a receptor tyrosine kinase inhibitor, which acts on the epidermal growth factor receptor (EGFR).^[3]

Erlotinib was approved for medical use in the United States in 2004.^[5]^[3]^[4] It is on the World Health Organization's List of Essential Medicines.^[6] In the United States, as of 2019^[update], it costs about US$8,832 per month.^[7] In the United Kingdom this amount costs the NHS about £1,632 per month.^[8]

References[edit]

^ ^a ^b "Erlotinib (Tarceva) Use During Pregnancy". Drugs.com. 1 November 2019. Retrieved 23 December 2019.
^ "WHOCC - ATC/DDD Index". www.whocc.no. Retrieved 10 September 2020.
^ ^a ^b ^c ^d ^e ^f ^g ^h "Erlotinib Monograph for Professionals". Drugs.com. Retrieved 12 November 2019.
^ ^a ^b "Tarceva- erlotinib hydrochloride tablet". DailyMed. 12 December 2018. Retrieved 23 December 2019.
^ "Drug Approval Package: Tarceva (Erlotinib) NDA #021743". U.S. Food and Drug Administration (FDA). 28 March 2005. Retrieved 23 December 2019.
^ Organization, World Health (2019). "World Health Organization model list of essential medicines: 21st list 2019" (Document). hdl:10665/325771. {{cite document}}: Cite document requires |publisher= (help)
^ "Tarceva Prices, Coupons & Patient Assistance Programs". Drugs.com.
^ British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 950. ISBN 9780857113382.